Literature DB >> 6469506

Chemical characterization of ASTA Z 7557 (INN mafosfamide, CIS-4-sulfoethylthio-cyclophosphamide), a stable derivative of 4-hydroxy-cyclophosphamide.

U Niemeyer, J Engel, G Scheffler, K Molge, D Sauerbier, W Weigert.   

Abstract

The primary metabolite of cyclophosphamide (CP, 1), i.e. 4-hydroxy-CP 2, has high pharmacological activity, but it is a very unstable compound. Chemical approaches to the stabilization involved in the substitution of the hydroxy group at the C 4-position, especially by a sulfoalkylthio-moiety. Within this new class of compounds ASTA Z 7557 (2-(bis-(2-chloroethyl]-amino-cis-4-[2-sulfoethyl)-thio)-tetrah ydr o-2H-1,3, 2-oxaza-phosphorine-r-2-oxide cyclohexylamine salt, i.e. cis-4-sulfoethylthio-CP, cis-13) was chosen for further evaluation. Cis-13 was synthesized by condensation of compound 2 and 2-mercapto-ethanesulfonic acid cyclohexylamine salt 14 in aqueous acetone yielding the cis-isomer with high stereoselectivity. It is a white crystalline powder, m.p. 126-134 degrees C, stable at room temperature, with a solubility of 16% in water. The stereochemistry was confirmed by NMR-data and X-ray diffraction. In 0.07 M phosphate buffer at pH 7 and 37 degrees C cis-13 isomerizes to the epimer trans-13, equilibrating at a cis-trans-ratio of 59 to 41 within less than 5 minutes. Simultaneously a rapid initial hydrolysis occurs to 2 and 14 followed by a time period with lower degradation due to the decomposition of 2. The rate of release of 2 increases with decreasing concentration and especially by addition of an oxidant. It could be retarded by addition of the corresponding thiol mesna, sodium 2-mercapto-ethanesulfonate 15, or of another thiol.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6469506     DOI: 10.1007/bf00232342

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


  8 in total

1.  Tissue sulfhydryl groups.

Authors:  G L ELLMAN
Journal:  Arch Biochem Biophys       Date:  1959-05       Impact factor: 4.013

2.  Alkylating properties of phosphoramide mustard.

Authors:  M Colvin; R B Brundrett; M N Kan; I Jardine; C Fenselau
Journal:  Cancer Res       Date:  1976-03       Impact factor: 12.701

3.  Acrolein, the causative factor of urotoxic side-effects of cyclophosphamide, ifosfamide, trofosfamide and sufosfamide.

Authors:  N Brock; J Stekar; J Pohl; U Niemeyer; G Scheffler
Journal:  Arzneimittelforschung       Date:  1979

4.  Studies on 4-hydroperoxycyclophosphamide (NSC-181815): a simple preparation method and its application for the synthesis of a new class of "activated" sulfur-containing cyclophosphamide (NSC-26271) derivatives.

Authors:  G Peter; T Wagner; H J Hohorst
Journal:  Cancer Treat Rep       Date:  1976-04

5.  Deactivation of cyclophosphamide (NSC-26271) metabolites by sulfhydryl compounds.

Authors:  J Draeger; G Peter; H J Hohorst
Journal:  Cancer Treat Rep       Date:  1976-04

6.  Synthesis and preliminary antitumor evaluation of 4-(SR)-sulfido-cyclophosphamides.

Authors:  G Peter; H J Hohorst
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

7.  Antitumor activity of monomeric and polymeric cyclophosphamide derivatives compared with in vitro hydrolysis.

Authors:  T Hirano; H Ringsdorf; D S Zaharko
Journal:  Cancer Res       Date:  1980-07       Impact factor: 12.701

8.  Conversion of 4-hydroperoxycyclophosphamide and 4-hydroxycyclophosphamide to phosphoramide mustard and acrolein mediated by bifunctional catalysis.

Authors:  J E Low; R F Borch; N E Sladek
Journal:  Cancer Res       Date:  1982-03       Impact factor: 12.701

  8 in total
  10 in total

Review 1.  Bone marrow purging with mafosfamide--a critical survey.

Authors:  H Sindermann; M Peukert; P Hilgard
Journal:  Blut       Date:  1989-11

2.  Possible role of histone acetylation and histone H1(0) replacement for the initiation of replication in regenerating rat liver.

Authors:  G Weiss; H Talasz; B Puschendorf
Journal:  Biochem J       Date:  1991-12-15       Impact factor: 3.857

3.  Influence of low doses of an oxazaphosphorine on natural killer activity of human lymphocytes.

Authors:  H Blomgren
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

4.  Successful chemoimmunotherapy of murine L1210 lymphatic leukemia with cyclophosphamide and mafosfamide-treated leukemia cells.

Authors:  M Kawalec; T Skórski; J Kawiak
Journal:  Invest New Drugs       Date:  1988-09       Impact factor: 3.850

5.  Nigericin enhances mafosfamide cytotoxicity at low extracellular pH.

Authors:  E Jähde; K H Glüsenkamp; M F Rajewsky
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

6.  Cyclophosphamides as hypoxia-activated diffusible cytotoxins: a theoretical study.

Authors:  J H Wu; C A Reynolds
Journal:  J Comput Aided Mol Des       Date:  2000-05       Impact factor: 3.686

7.  Cause and prevention of mafosfamide-induced venous pain.

Authors:  P Hilgard; J Pohl
Journal:  Invest New Drugs       Date:  1986       Impact factor: 3.850

8.  Possible role of acrolein in oxazaphosphorine-induced enhancement of immunological reactivity.

Authors:  H Blomgren; M Hallström
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

9.  Regional fibrosis after intraperitoneal administration of mafosfamide.

Authors:  J D Roberts; R A Newman; P J Kimberly; M P Hacker
Journal:  Invest New Drugs       Date:  1986       Impact factor: 3.850

10.  Comparison of in vitro activity of epipodophyllotoxins with other chemotherapeutic agents in human medulloblastomas.

Authors:  F H Tomlinson; M G Lihou; P J Smith
Journal:  Br J Cancer       Date:  1991-12       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.